Industry: Healthcare | Publish Date: 06-Jul-2024 | No of Pages: 139 | No. of Tables: 104 | No. of Figures: 69 | Format: PDF | Report Code : N/A
The Canada In-Vitro Diagnostics Market size was valued at USD 4.28 billion in 2023, and is predicted to reach USD 6.51 billion by 2030, at a CAGR of 5.7% from 2024 to 2030. In-vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions. These tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology.
IVD tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, these tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics. Also, immunoassay experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges.
Expansion in healthcare expenditure is significantly driving the in-vitro diagnostics market growth in the region. The Canadian medical Association reported that, Canada allocates about USD 220 billion annually towards healthcare expenditure.
As healthcare expenditure increases, there is a greater allocation of resources towards improving healthcare infrastructure, enhancing medical facilities, and expanding access to healthcare services, including immunodiagnostic testing.
This includes the adoption of innovative products and platforms that offer more accurate, efficient, and timely diagnostic. These investments enable healthcare facilities to enhance their diagnostic capabilities, improve patient care, and achieve better treatment outcomes.
The expansion of an international molecular diagnostics group in the country, aimed at providing various molecular diagnostics services to the Canadian population, significantly contributes to the Canada of the in-vitro diagnostics market growth.
By offering a diverse range of molecular diagnostic tests and services, including those for infectious diseases, genetic disorders, and cancer, this initiative enhances access to advanced diagnostic solutions. For instance, in January 2022, Yourgene, an international molecular diagnostics group, announced the launch of its expanded facilities by Yourgene Health Canada Inc.
This expansion reflects Yourgene's strategic alignment with anticipated growth in instrument manufacturing and consumable shipping demands, demonstrating their dedication to addressing the increasing need for molecular diagnostics in Canada.
By enhancing manufacturing capabilities, Yourgene aims to contribute to the advancement of the in-vitro diagnostics market and facilitate the delivery of innovative diagnostic solutions to healthcare providers and patients nationwide.
High costs associated with research, development, and regulatory approval are significant factors restraining the market growth. Operating within this sector necessitates significant financial investment for companies to navigate the complex landscape of research and development.
This investment often encompasses extensive clinical trials, laboratory testing, and product refinement to guarantee accuracy and reliability. Additionally, obtaining regulatory approvals from agencies such as the FDA requires strict adherence to stringent standards, further compounding the financial burden. This financial constraint can discourage potential adopters from the Canada IVD market expansion.
Point-of-care testing (POCT) is poised to be a significant driver of the Canada in-vitro diagnostics market demand in the forthcoming years. POCT serves as a valuable complement to laboratory testing, especially in situations where immediate results are crucial, such as emergency departments, ambulances, and remote healthcare settings.
With POCT technologies offering rapid tests for infectious diseases, cardiac biomarkers, glucose monitoring, pregnancy testing, and more, healthcare providers can quickly assess patients' conditions and make timely treatment decisions.
By integrating POCT with traditional IVD, healthcare providers can enhance their diagnostic capabilities, delivering more efficient and patient-centered care. This integration streamlines workflows, allowing for faster diagnosis and treatment initiation, ultimately leading to improved patient outcomes.
The promising players operating in the Canada in-vitro diagnostics industry include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.
Reagents
Instruments
Software & Services
Immunodiagnostics
Enzyme-Linked Immunosorbent Assay (ELISA)
Rapid Tests
Chemiluminescence Immunoassay (CLIA)
Enzyme-linked Immunosorbent spot (ELISpot)
Radioimmunoassay (RIA)
Western Blot
Hematology
Molecular Diagnostics
PCR
INAAT
Hybridization
DNA diagnostics
Microarray
Other Molecular Diagnostics
Tissue Diagnostics
Clinical Chemistry
Basic Metabolic Panel
Liver Panel
Renal Profile
Lipid Profile
Thyroid Function Panel
Electrolyte Panel
Speciality Chemicals
Other IVD Techniques
Infectious Diseases
Cancer
Cardiac Diseases
Immune System Disorders
Nephrological Diseases
Gastrointestinal Diseases
Others
Stand Alone Laboratory
Hospitals
Academics and Medical Schools
Point of Care Testing
Other End Users
REPORT SCOPE AND SEGMENTATION:
Parameters |
Details |
Market Size Value in 2023 |
USD 4.28 billion |
Revenue Forecast in 2030 |
USD 6.51 billion |
Value Growth Rate |
CAGR of 5.7% from 2024 to 2030 |
Analysis Period |
2023–2030 |
Base Year Considered |
2023 |
Forecast Period |
2024–2030 |
Market Size Estimation |
Million (USD) |
Growth Factors |
|
Companies Profiled |
10 |
Customization Scope |
Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope. |
Pricing and Purchase Options |
Avail customized purchase options to meet your exact research needs. |
Roche Holding AG
Abbott Laboratories
Thermo Fisher Scientific Inc.
Danaher Corporation
Becton, Dickinson and Company
Siemens Healthineers AG
bioMérieux SA
Sysmex Corporation
QIAGEN N.V.
Bio-Rad Laboratories, Inc.